

April 26, 2024

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400001
Company Code No. 526301

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on April 26, 2024.

We hereby inform you that, the Board of Directors at its meeting held today i.e. on **Friday, April 26, 2024**, has inter-alia considered and approved:

1. The Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and financial year ended March 31, 2024

A signed copy of the above financial results along with Audit Report issued by M/s. M. Anandam & Co., Chartered Accountants, Statutory Auditors of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed to this letter.

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm and declare that our Statutory Auditors, M/s. M. Anandam & Co., issued the Audit Report with “unmodified opinion” on the Audited Standalone and Consolidated Financial Results for the financial year ended March 31, 2024.

2. Completion of term of Mr. K. V. Ravindra Reddy

Mr. K. V. Ravindra Reddy (DIN: 00083986), has completed his second term of five (5) years as an Independent Director of the Company on March 31, 2024, and ceased to be an Independent Director of the Company thereafter.

The Board took note of the said term completion.

3. Re-appointment of Mr. Sunil Chandra Kondapally as Managing Director of the Company

The Board, based on the recommendation of the Nomination and Remuneration Committee, has re-appointed Mr. Sunil Chandra Kondapally (DIN:01409332) as Managing Director of the

Company for a further period of five (5) years with effect from September 25, 2024, subject to approval of the shareholders at the forthcoming Annual General Meeting of the Company.

The details pertaining to re-appointment as per SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are mentioned in Annexure-A.

The Meeting commenced at 12:30 P.M. (IST) and concluded at 1:30 P.M. (IST)

Kindly take the same on record. Thanking You.

Yours Truly,
For **Medinova Diagnostic Services Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M.No.F11438

Encl.: As above

Annexure – A

Details Pertaining to Re-appointment

S. No.	Particulars	Remarks
1.	Name	Mr. Sunil Chandra Kondapally (DIN:01409332)
2.	Reason for change viz., appointment, resignation, removal, death or otherwise	Re-appointment as Managing Director of the Company
3.	Date of Appointment	With effect from September 25, 2024
4.	Term of Appointment	Re-appointed for a period of five (5) consecutive years effective from September 25, 2024, till September 24, 2029, subject to the approval of shareholders at the ensuing AGM.
5.	Brief Profile	Mr. Sunil Chandra Kondapally is the Managing Director of the Company. He is also an Executive Director of Vijaya Diagnostic Centre Limited. He holds a bachelor's degree in science in electrical engineering from Florida State University. He has over 17 years of experience in the field of pharmaceutical industry. He founded a pharmaceutical services company Trikona Pharmaceuticals Private Limited in 2016 and QPS Bioserve India Private Limited in 2004 and, which focuses on the development of innovative pharmaceutical products. He has worked in operations, quality accreditation, finance, marketing and network expansion departments of Vijaya Diagnostic Centre Limited since its incorporation.
6.	Disclosure of Relationship between Directors	<ol style="list-style-type: none"> 1. Dr. Sura Surendranath Reddy, Non-executive Chairman – Father 2. Mrs. B Vishnu Priya Reddy, Non-executive Director – Spouse
7.	Declaration	We hereby affirm that Mr. Sunil Chandra Kondapally is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.